Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1986 1
1987 2
1988 2
1989 2
1991 1
1993 1
1995 1
1997 1
1998 3
1999 4
2000 2
2001 2
2002 6
2004 3
2005 1
2006 3
2007 3
2008 5
2009 1
2010 5
2011 5
2012 6
2013 8
2014 7
2015 7
2016 8
2017 8
2018 14
2019 10
2020 10
2021 6
2022 10
2023 5
2024 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. Morschhauser F, et al. N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. N Engl J Med. 2018. PMID: 30184451 Free PMC article. Clinical Trial.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Mateos MV, et al. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12. N Engl J Med. 2018. PMID: 29231133 Free article. Clinical Trial.
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
Paiva B, Puig N, Cedena MT, Rosiñol L, Cordón L, Vidriales MB, Burgos L, Flores-Montero J, Sanoja-Flores L, Lopez-Anglada L, Maldonado R, de la Cruz J, Gutierrez NC, Calasanz MJ, Martin-Ramos ML, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Blanchard MJ, Rios R, Martin J, Martinez-Martinez R, Sureda A, Hernandez MT, de la Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, Van Dongen JJM, Orfao A, Mateos MV, Blade J, San-Miguel JF, Lahuerta JJ; GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group. Paiva B, et al. Among authors: palomera l. J Clin Oncol. 2020 Mar 10;38(8):784-792. doi: 10.1200/JCO.19.01231. Epub 2019 Nov 26. J Clin Oncol. 2020. PMID: 31770060 Free article.
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Rosiñol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernández MT, Martínez-Martínez R, Moraleda JM, Jarque I, Bargay J, Gironella M, de Arriba F, Palomera L, González-Montes Y, Martí JM, Krsnik I, Arguiñano JM, González ME, González AP, Casado LF, López-Anglada L, Paiva B, Mateos MV, San Miguel JF, Lahuerta JJ, Bladé J. Rosiñol L, et al. Among authors: palomera l. Blood. 2019 Oct 17;134(16):1337-1345. doi: 10.1182/blood.2019000241. Blood. 2019. PMID: 31484647 Free PMC article. Clinical Trial.
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.
Alameda D, Goicoechea I, Vicari M, Arriazu E, Nevone A, Rodriguez S, Lasa M, Puig N, Cedena MT, Alignani D, Garate S, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Ocio EM, Lecumberri R, Garcia de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabañas V, Casanova M, Oriol A, Krsnik I, Perez-Montaña A, de la Rubia J, de la Puerta JE, de Arriba F, Fazio VM, Martinez-Lopez J, Lahuerta JJ, Mateos MV, Odero MD, Prosper F, Weiner A, Amit I, Nuvolone M, San Miguel JF, Paiva B. Alameda D, et al. Among authors: palomera l. Blood. 2021 Oct 28;138(17):1583-1589. doi: 10.1182/blood.2020009754. Blood. 2021. PMID: 34133718 Free article.
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.
Botta C, Perez C, Larrayoz M, Puig N, Cedena MT, Termini R, Goicoechea I, Rodriguez S, Zabaleta A, Lopez A, Sarvide S, Blanco L, Papetti DM, Nobile MS, Besozzi D, Gentile M, Correale P, Siragusa S, Oriol A, González-Garcia ME, Sureda A, de Arriba F, Rios Tamayo R, Moraleda JM, Gironella M, Hernandez MT, Bargay J, Palomera L, Pérez-Montaña A, Goldschmidt H, Avet-Loiseau H, Roccaro A, Orfao A, Martinez-Lopez J, Rosiñol L, Lahuerta JJ, Blade J, Mateos MV, San-Miguel JF, Martinez Climent JA, Paiva B; Programa Para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) cooperative group; iMMunocell study group. Botta C, et al. Among authors: palomera l. Nat Commun. 2023 Sep 20;14(1):5825. doi: 10.1038/s41467-023-41562-6. Nat Commun. 2023. PMID: 37730678 Free PMC article.
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Rosiñol L, Oriol A, Ríos R, Blanchard MJ, Jarque I, Bargay J, Hernández MT, Cabañas V, Carrillo-Cruz E, Sureda A, Martínez-López J, Krsnik I, González ME, Casado LF, Martí JM, Encinas C, de Arriba F, Palomera L, Sampol A, González-Montes Y, Cabezudo E, Paiva B, Puig N, Cedena MT, de la Cruz J, Mateos MV, San Miguel J, Lahuerta JJ, Bladé J. Rosiñol L, et al. Among authors: palomera l. Blood. 2023 Nov 2;142(18):1518-1528. doi: 10.1182/blood.2022019531. Blood. 2023. PMID: 37506339 Free article. Clinical Trial.
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Guerrero C, Jelínek T, Johnson S, Milani P, Cordon L, Perez JJ, Lasa M, Termini R, Oriol A, Hernandez MT, Palomera L, Martinez-Martinez R, de la Rubia J, de Arriba F, Rios R, Gonzalez ME, Gironella M, Cabañas V, Casanova M, Krsnik I, Perez-Montaña A, González-Calle V, Rodriguez-Otero P, Maisnar V, Hajek R, Van Rhee F, Jimenez-Zepeda V, Palladini G, Merlini G, Orfao A, de la Cruz J, Martinez-Lopez J, Lahuerta JJ, Rosiñol L, Blade J, Mateos MV, San-Miguel JF, Paiva B; PETHEMA/GEM Cooperative Group. Burgos L, et al. Among authors: palomera l. J Clin Oncol. 2023 Jun 1;41(16):3019-3031. doi: 10.1200/JCO.22.01916. Epub 2023 Mar 17. J Clin Oncol. 2023. PMID: 36930848
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.
Guerrero C, Puig N, Cedena MT, Calasanz MJ, Gutierrez NC, Fernandez M, Oriol A, Ríos-Tamayo R, Hernandez MT, Martínez-Martínez R, Bargay J, de Arriba F, Palomera L, Gonzalez-Rodriguez AP, Gonzalez Perez MS, Orfao A, Mateos MV, Martinez-Lopez J, Rosiñol L, Bladé J, Lahuerta JJ, San-Miguel JF, Paiva B. Guerrero C, et al. Among authors: palomera l. Blood. 2024 Feb 15;143(7):597-603. doi: 10.1182/blood.2023022083. Blood. 2024. PMID: 38048552
Dysregulation of histone deacetylases in ocular diseases.
Jun JH, Kim JS, Palomera LF, Jo DG. Jun JH, et al. Among authors: palomera lf. Arch Pharm Res. 2024 Jan;47(1):20-39. doi: 10.1007/s12272-023-01482-x. Epub 2023 Dec 27. Arch Pharm Res. 2024. PMID: 38151648 Review.
150 results